About RAS Mutation Clearance in Plasma ctDNA From RAS-Mutant Colorectal Cancer Patients
- 1 November 2021
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 5 (5), 389-390
- https://doi.org/10.1200/po.20.00376
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- UndetectableRAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients WithRAS-Mutant Metastatic Colorectal CancerJCO Precision Oncology, 2020
- Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal CancerFrontiers in Oncology, 2019
- Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal CancerCancers, 2019
- EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize TreatmentJCO Precision Oncology, 2018
- Second line EGFR-inhibitors in RAS mutant metastatic colorectal cancer: The plasma RAS wild type “window of opportunity”Annals of Oncology, 2018
- ctDNA might expand therapeutic options for second line treatment of KRAS mutant mCRCAnnals of Oncology, 2017